iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Historical Holders from Q3 2020 to Q3 2025

Type / Class: Equity / Common stock, par value $0.001 per share
Symbol: ITOS
Shares outstanding: 37,972,605
Price per share: $11.56
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 217
Total reported value: $2,508
% of total 13F portfolios: 0%
Share change: -37,776,459
Value change: -$376,632,286
Number of holders: 1
Price from insider filings: $11.56

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
EcoR1 Capital, LLC	28%	+87%	$78,563,988	+$36,448,488	10,688,978	+87%	EcoR1 Capital, LLC	15 May 2025
BlackRock Portfolio Management LLC	6.1%		$13,163,523		2,329,827		BlackRock Portfolio Management LLC	31 Mar 2025
BlackRock, Inc.	5.7%		$12,313,723		2,179,420		BlackRock, Inc.	31 Mar 2025
RA CAPITAL MANAGEMENT, L.P.	4.9%	-50%	$15,690,824	-$14,909,254	2,134,806	-49%	RA Capital Management, L.P.	15 May 2025
MPM BioVentures 2014, L.P.	4.7%		$10,192,577		1,803,996		ANSBERT GADICKE	13 May 2025
TANG CAPITAL MANAGEMENT LLC	100%	+900%	$102,100	-$38,968,425	10,000	-100%	TANG CAPITAL MANAGEMENT, LLC	29 Aug 2025

As of 30 Sep 2025, iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) has 1 institutional shareholder filing 13F forms. They hold 217 shares. of 37,972,605 outstanding shares (0%) .

Institutional Holders of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	217	$2,508	-$376,632,286	$0	$0	$11.56	1
2025 Q2	37,814,070	$377,007,329	+$70,828,927	$6,092,667	$7,308,010	$9.97	134
2025 Q1	36,966,178	$220,688,468	+$13,034,796	$4,406,457	$724,758	$5.97	128
2024 Q4	34,139,228	$262,177,743	-$45,402,032	$18,816,768	$3,486,720	$7.68	133
2024 Q3	36,577,848	$373,304,710	-$1,632,047	$3,819,561	$19,861,513	$10.21	146
2024 Q2	36,167,031	$536,759,881	+$29,434,774	$21,917,196	$9,683,100	$14.84	132
2024 Q1	34,203,997	$466,473,509	-$7,323,134	$439,208	$1,153,944	$13.64	126
2023 Q4	80,240	$878,629	+$635,713			$10.95	2
2023 Q3	35,485,163	$388,562,382	+$6,644,520	$2,357,535	$3,103,230	$10.95	141
2023 Q2	34,539,222	$457,304,963	-$19,192,735	$937,392	$1,192,924	$13.24	140
2023 Q1	35,981,503	$488,850,193	-$8,814,002	$592,035	$307,586	$13.61	149
2022 Q4	36,200,782	$707,272,137	-$15,776,830	$259,749	$1,014,107	$19.53	144
2022 Q3	35,563,534	$677,471,610	-$16,146,542	$0	$192,000	$19.05	131
2022 Q2	35,261,080	$723,422,287	-$10,851,198	$941,000	$4,886,000	$20.60	143
2022 Q1	35,126,415	$1,130,234,371	+$60,160,680	$2,070,000	$315,000	$32.18	149
2021 Q4	32,640,335	$1,518,014,842	+$93,868,008			$46.56	113
2021 Q3	30,994,904	$837,029,161	+$53,985,818			$27.00	75
2021 Q2	29,374,668	$753,447,849	-$19,714,194			$25.65	81
2021 Q1	30,077,083	$1,028,007,222	+$90,244,510			$34.18	75
2020 Q4	25,798,168	$869,553,074	+$60,260,687			$33.82	69
2020 Q3	24,529,370	$603,768,488	+$545,656,612			$24.67	53